Back to Search
ELIAS JABBOUR, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1215108303IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
P8368(TX)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1998
Research & Publications (20)
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
PMID 19365094·Oncologist·2009
6-review
Treatment selection after imatinib resistance in chronic myeloid leukemia.
PMID 19343297·Target Oncol·2009
6-review
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
PMID 19621546·Semin Hematol·2009
8-other
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
PMID 19235255·Cancer·2009
8-other
Treatment of myelofibrosis in younger patients: to transplant or not?
PMID 19202548·Am J Hematol·2009
8-other
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
PMID 19181650·Mayo Clin Proc·2009
6-review
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
PMID 19060245·Blood·2009
3-trial
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
PMID 18818391·Blood·2008
8-other
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
PMID 18549348·Expert Opin Investig Drugs·2008
7-preclinical
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
PMID 19254884·Clin Lymphoma Myeloma·2008
6-review
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
PMID 18403620·Blood·2008
8-other
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
PMID 18398832·Cancer·2008
6-review
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
PMID 18348294·Cancer·2008
6-review
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
PMID 18186499·Cancer·2008
6-review
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
PMID 17564324·Oncology (Williston Park)·2007
6-review
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
PMID 17849460·Cancer·2007
3-trial
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
PMID 17642017·IDrugs·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1215108303
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile